Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

LASS1 antibody (AA 301-350)

CERS1 Reactivity: Human WB, ELISA Host: Mouse Polyclonal unconjugated
Catalog No. ABIN564667
  • Target See all LASS1 (CERS1) Antibodies
    LASS1 (CERS1) (Ceramide Synthase 1 (CERS1))
    Binding Specificity
    • 6
    • 2
    • 2
    • 1
    • 1
    AA 301-350
    Reactivity
    • 20
    • 5
    • 4
    • 2
    • 1
    Human
    Host
    • 18
    • 1
    • 1
    Mouse
    Clonality
    • 19
    • 1
    Polyclonal
    Conjugate
    • 10
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This LASS1 antibody is un-conjugated
    Application
    • 9
    • 9
    • 3
    Western Blotting (WB), ELISA
    Purpose
    Mouse polyclonal antibody raised against a partial recombinant LASS1.
    Sequence
    YIVAFAAKVL TGQVHELKDL REYDTAEAQS LKPSKAEKPL RNGLVKDKRF
    Cross-Reactivity
    Human
    Characteristics
    Antibody Reactive Against Recombinant Protein.
    Immunogen
    LASS1 (NP_067090, 301 a.a. ~ 350 a.a) partial recombinant protein with GST tag.
    Top Product
    Discover our top product CERS1 Primary Antibody
  • Application Notes
    Optimal working dilution should be determined by the investigator.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    50 % glycerol
    Handling Advice
    Aliquot to avoid repeated freezing and thawing.
    Storage
    -20 °C
    Storage Comment
    Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
  • Separovic, Breen, Joseph, Bielawski, Pierce, VAN Buren, Gudz: "Ceramide synthase 6 knockdown suppresses apoptosis after photodynamic therapy in human head and neck squamous carcinoma cells." in: Anticancer research, Vol. 32, Issue 3, pp. 753-60, (2012) (PubMed).

    Separovic, Breen, Joseph, Bielawski, Pierce, VAN Buren, Gudz: "siRNA-mediated down-regulation of ceramide synthase 1 leads to apoptotic resistance in human head and neck squamous carcinoma cells after photodynamic therapy." in: Anticancer research, Vol. 32, Issue 7, pp. 2479-85, (2012) (PubMed).

    Haddad, Khoury, Daoud, Kantar, Harati, Mousallem, Alzate, Meyer, Boustany: "CLN5 and CLN8 protein association with ceramide synthase: biochemical and proteomic approaches." in: Electrophoresis, Vol. 33, Issue 24, pp. 3798-809, (2012) (PubMed).

    Senkal, Ponnusamy, Bielawski, Hannun, Ogretmen: "Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways." in: FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 24, Issue 1, pp. 296-308, (2010) (PubMed).

    Senkal, Ponnusamy, Rossi, Bialewski, Sinha, Jiang, Jazwinski, Hannun, Ogretmen: "Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas." in: Molecular cancer therapeutics, Vol. 6, Issue 2, pp. 712-22, (2007) (PubMed).

  • Target
    LASS1 (CERS1) (Ceramide Synthase 1 (CERS1))
    Alternative Name
    LASS1 (CERS1 Products)
    Synonyms
    LAG1 antibody, LASS1 antibody, UOG1 antibody, Lass1 antibody, Uog-1 antibody, to antibody, LAG1 HOMOLOG 1 antibody, LONGEVITY ASSURANCE GENE 1 antibody, ceramide synthase 1 antibody, TRAM, LAG1 and CLN8 (TLC) lipid-sensing domain containing protein antibody, CERS1 antibody, Cers1 antibody, LAG1 antibody
    Background
    Full Gene Name: LAG1 homolog, ceramide synthase 1
    Synonyms: CerS1,LAG1,MGC90349,UOG1
    Gene ID
    10715
    NCBI Accession
    NM_021267
You are here:
Support